CHAPEL HILL, NC--(Marketwired - May 8, 2013) - Crown Marketing Inc. (
The Company's objectives will be two fold. Firstly, it hopes to provide ancillary services such as financing and other "back room" support to companies in the field of medical marijuana, an industry which remains largely shunned by main stream business support professionals. These possibilities are being evaluated on a case-by-case basis.
Secondly, JVS intends to employ most or all of the free cash flow generated from support services to research the benefits of Crown's novel patented controlled delivery device with respect to cannabinoids and more specifically to Cannabidiol, or CBDs.
CBDs are present in almost all strains of the cannabis plant. CBDs are believed to possess many of the therapeutic qualities of THC, but without the psychotropic effects (no "high"). For these reasons, CBDs are considered highly marketable to the segment of the population interested in marijuana related products for the medical benefits but who shy away from the alteration of mood and perception associated with consumption of THC. Because CBDs lack the psychoactive compounds banned under various legal frameworks, CBDs may be marketed nationwide. Moreover, preliminary research indicates that precision time release of CBDs available with Crown's controlled drug delivery technology would not only render consumption more convenient, but would also dramatically improve the pharmacological profile of these compounds, thereby yielding greater medical benefits.
About The Company:
The parent of the new subsidiary, Crown Marketing's Controlled Drug Delivery Technology (CDDT) holds patents for a novel controlled-release technology, harnessing the principles of chaos theory, precise mathematical formulas and the potentials of chemical diffusion characteristics.
The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chrono-therapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.
The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.
Crown's cost-effective application of controlled delivery technologies may play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.
More information can be found at: www.crowncddt.com
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.
- Health Care Industry
Charles Van Der Ross